CDTX
Company Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Track Record
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 23.28M | 64.45M | 49.57M | 12.07M | 20.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.83M) | (22.93M) | (33.58M) | (42.47M) | (72.11M) | (41.09M) | (59.02M) | (55.73M) | (48.16M) | (32.19M) | (11.89M) | (1.34M) |
| EPS | -26.75 | -5.25 | -9.61 | -16.20 | -36.03 | -26.78 | -45.62 | -63.69 | -66.49 | -46.76 | -290.15 | -83.04 |
| Free Cash Flow | (176.66M) | (22.94M) | (28.59M) | (25.27M) | (54.60M) | (28.57M) | (56.88M) | (50.22M) | (40.17M) | (27.13M) | N/A | N/A |
| FCF / Share | -27.82 | -5.25 | -8.19 | -9.64 | -26.28 | -19.09 | -43.97 | -57.39 | -55.45 | -39.40 | N/A | N/A |
| Operating CF | (176.53M) | (22.43M) | (28.47M) | (25.23M) | (54.41M) | (28.53M) | (56.70M) | (49.91M) | (39.77M) | (25.96M) | N/A | N/A |
| Total Assets | 214.80M | 67.03M | 47.49M | 75.33M | 60.42M | 68.98M | 79.11M | 79.03M | 106.96M | 109.97M | N/A | N/A |
| Total Debt | 3.58M | 4.88M | 1.21M | 5.06M | 7.96M | 11.72M | 9.93M | 9.87M | 9.79M | 0 | N/A | N/A |
| Cash & Equiv | 189.82M | 35.78M | 32.73M | 62.27M | 35.91M | 50.27M | 74.56M | 75.31M | 104.62M | 107.51M | N/A | N/A |
| Book Value | 163.31M | (8.21M) | (14.44M) | 21.57M | 10.71M | 37.84M | 59.14M | 59.74M | 88.18M | 103.91M | N/A | N/A |
| Return on Equity | -1.04 | N/A | N/A | -1.97 | -6.73 | -1.09 | -1.00 | -0.93 | -0.55 | -0.31 | N/A | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 302,000 | 973,000 | 17.58M | 9.22M | 5.09M | 26.11M | 10.22M |
| Net Income | (83.23M) | (25.72M) | (23.48M) | (52.31M) | (15.98M) | (91.21M) | (10.33M) | (5.61M) | (9.11M) | (13.62M) | 3.01M | (13.38M) |
| EPS | -3.10 | -1.65 | -1.66 | -5.37 | -2.38 | -19.59 | -2.28 | -1.25 | -1.81 | -2.80 | 0.77 | -3.72 |
| Free Cash Flow | (40.62M) | (40.96M) | (21.95M) | (29.41M) | (36.80M) | (103.78M) | (6.67M) | (12.90M) | (1.76M) | 2.71M | (10.99M) | (21.01M) |
| FCF / Share | -2.61 | -2.63 | -1.55 | -3.02 | -5.64 | -22.74 | -1.47 | -2.87 | -0.39 | 0.62 | -2.80 | -5.84 |
| Operating CF | (40.62M) | (40.96M) | (21.95M) | (29.41M) | (36.70M) | (103.78M) | (6.64M) | (12.72M) | (1.63M) | 2.82M | (10.90M) | (21.00M) |
| Total Assets | 518.65M | 534.33M | 191.73M | 214.80M | 162.33M | 173.36M | 52.72M | 67.03M | 63.47M | 67.99M | 81.74M | 47.49M |
| Total Debt | 1.98M | 2.33M | 2.67M | 3.58M | 3.94M | 4.30M | 4.65M | 4.88M | 4.36M | 4.54M | 1.00M | 1.21M |
| Cash & Equiv | 293.65M | 510.57M | 168.15M | 189.82M | 127.39M | 164.37M | 29.02M | 35.78M | 48.67M | 50.43M | 47.98M | 32.73M |
| Book Value | 422.39M | 501.17M | 141.68M | 163.31M | 115.63M | 130.94M | (17.78M) | (8.21M) | 8.04M | 15.41M | 26.84M | (14.44M) |
| Return on Equity | -0.20 | -0.05 | -0.17 | -0.32 | -0.14 | -0.70 | N/A | N/A | -1.13 | -0.88 | 0.11 | N/A |
